Vaccine review: "Staphyloccocus aureus vaccines: Problems and prospects"

Vaccine

Volumn 31, Issue 25, 2013, Pages 2723-2730

  Jansen, Kathrin U ^a   Girgenti, Douglas Q ^a   Scully, Ingrid L ^a   Anderson, Annaliesa S ^a  

^a PFIZER INC   (United States)

Author keywords

Immune response; Patient population; S. aureus; Staphylococcus; Vaccine

Indexed keywords

ALTASTAPH; AUROGRAB; KBSA 301; MEDI 4893; NDV 3; PAGIBAXIMAB; PF 06290510; SAR 279356; STAPHYBAN; STAPHYLOCOCCUS VACCINE; STEBVAX; TEFIBAZUMAB; UNCLASSIFIED DRUG; V 710; VERONATE;

ANTIBIOTIC RESISTANCE; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; GENERAL SURGERY; GYNECOLOGIC SURGERY; HEALTH CARE NEED; HEALTH CARE SYSTEM; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; INCIDENCE; NEUROSURGERY; ORTHOPEDIC SURGERY; PHASE 3 CLINICAL TRIAL (TOPIC); PLASTIC SURGERY; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION; THORAX SURGERY; TREATMENT RESPONSE; VACCINATION; VASCULAR SURGERY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; VACCINATION;

EID: 84878359457     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.002     Document Type: Review

References (154)

1. Lowy F.D. How Staphylococcus aureus adapts to its host. N Engl J Med 2011, 364:1987-1990.
2. Wertheim H.F.L., Melles D.C., Vos M.C., van Leeuwen W., van Belkum A., Verbrugh H.A., et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005, 5:751-762.
3. Anderson D.J., Chen L.F., Schmader K.E., Sexton D.J., Choi Y., Link K., et al. Poor functional status as a risk factor for surgical site infection due to methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am 2008, 29:832-839.
4. Harrington G., Russo P., Spelman D., Borrell S., Watson K., Barr W., et al. Surgical-site infection rates and risk factor analysis in coronary artery bypass graft surgery. Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am 2004, 25:472-476.
5. Kaye K.S., Schmit K., Pieper C., Sloane R., Caughlan K.F., Sexton D.J., et al. The effect of increasing age on the risk of surgical site infection. J Infect Dis 2005, 191:1056-1062.
6. Miller M.B., Weber D.J., Goodrich J.S., Popowitch E.B., Poe M.D., Nyugen V., et al. Prevalence and risk factor analysis for methicillin-resistant Staphylococcus aureus nasal colonization in children attending child care centers. J Clin Microbiol 2011, 49:1041-1047.
7. Kupfer M., Jatzwauk L., Monecke S., Mobius J., Weusten A. MRSA in a large German University Hospital: male gender is a significant risk factor for MRSA acquisition. GMS Krankenh Interdiszipl 2010, 5.
8. Junqueira B.L., Connolly B., Abla O., Tomlinson G., Amaral J.G. Severe neutropenia at time of port insertion is not a risk factor for catheter-associated infections in children with acute lymphoblastic leukemia. Cancer 2010, 116:4368-4375.
9. McAllister L., Gaynes R.P., Rimland D., McGowan J.E. Hospitalization earlier than 1 year prior to admission as an additional risk factor for methicillin-resistant Staphylococcus aureus colonization. Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am 2010, 31:538-540.
10. Pishchany G., McCoy A.L., Torres V.J., Krause J.C., Crowe J.E., Fabry M.E., et al. Specificity for human hemoglobin enhances Staphylococcus aureus infection. Cell Host Microbe 2010, 8:544-550.
11. Veloso T.R., Chaouch A., Roger T., Giddey M., Vouillamoz J., Majcherczyk P., et al. Use of a human-like low-grade bacteremia model of experimental endocarditis to study the role of Staphylococcus aureus adhesins and platelet aggregation in early endocarditis. Infect Immun 2013, 81:697-703.
12. Del Giudice P., Tattevin P., Etienne J. Community-acquired methicillin-resistant Staphylococcus aureus. Rev Presse Med 2011, [ePub].
13. Furuya E.Y., Cook H.A., Lee M.H., Miller M., Larson E., Hyman S., et al. Community-associated methicillin-resistant Staphylococcus aureus prevalence: how common is it, A methodological comparison of prevalence ascertainment. Am J Infect Control 2007, 35:359-366.
14. Jacobson M., Gellermann H., Chambers H. Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex. Am J Med 1988, 85:172-176.
15. Kale-Pradhan P., Johnson L.B. Treatment and recurrence management of staphylococcal infections: community-acquired MRSA. Exp Rev Anti-infect Therapy 2008, 6:909-915.
16. Karamatsu M.L., Thorp A.W., Brown L. Changes in community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections presenting to the pediatric emergency department: comparing 2003-2008. Pediat Emerg Care 2012, 28:131-135. 10.1097/PEC.0b013e318243fa36.
17. Miller L.G., Kaplan S.L. Staphylococcus aureus: a community pathogen. Infect Dis Clin N Am 2009, 23:35-52.
18. Skov R., Christiansen K., Dancer S.J., Daum R.S., Dryden M., Huang Y.C., et al. Update on the prevention and control of community-acquired meticillin-resistant Staphylococcus aureus (CA-MRSA). Int J Antimicrob Agents 2012, 39:193-200.
19. Broughan J., Anderson R., Anderson A.S. Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines. Exp Rev Vaccines 2011, 10:695-708.
20. Edwards A.M., Massey R.C., Clarke S.R. Molecular mechanisms of Staphylococcus aureus nasopharyngeal colonization. Mol Oral Microbiol 2012, 27:1-10.
21. Peacock S.J., de Silva I., Lowy F.D. What determines nasal carriage of Staphylococcus aureus. Trends Microbiol 2001, 9:605-610.
22. DeLeo F.R., Diep B.A., Otto M., Host Defense Pathogenesis in Staphylococcus aureus infections. Infect Dis Clin N Am 2009, 23:17-34.
23. Is Lowy F.D. Staphylococcus aureus an intracellular pathogen. Trends Microbiol 2000, 8:341-343.
24. Tong S., Chen L., Fowler V. Colonization, pathogenicity, host susceptibility, and therapeutics for <i>Staphylococcus aureus</i>: what is the clinical relevance. Semin Immunopathol 2012, 34:185-200.
25. Cassat J.E., Skaar E.P. Metal ion acquisition in Staphylococcus aureus: overcoming nutritional immunity. Semin Immunopathol 2012, 34:215-235.
26. Kehres D.G., Maguire M.E. Emerging themes in manganese transport, biochemistry and pathogenesis in bacteria. FEMS Microbiol Rev 2003, 27:263-290.
27. Skaar E.P. The battle for iron between bacterial pathogens and their vertebrate hosts. PLoS Pathog 2010, 6:e1000949.
28. 2+ and bacterial pathogenesis. Front Biosci J Virt Library 2004, 9:1035-1042.
29. McDevitt D., Nanavaty T., House-Pompeo K., Bell E., Turner N., McIntire L., et al. Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur J Biochem 1997, 247:416-424.
30. Cheng A.G., DeDent A.C., Schneewind O., Missiakas D. A play in four acts: Staphylococcus aureus abscess formation. Trends Microbiol 2011, 19:225-232.
31. Chagnot C., Listrat A., Astruc T., Desvaux M. Bacterial adhesion to animal tissues: protein determinants for recognition of extracellular matrix components. Cell Microbiol 2012, 14:1687-1696.
32. Heilmann C. Adhesion mechanisms of staphylococci. Adv Exp Med Biol 2011, 715:105-123.
33. Abdulahad W.H., Stegeman C.A., Kallenberg C.G. Review article: the role of CD4(+) T cells in ANCA-associated systemic vasculitis. Nephrology 2009, 14:26-32.
34. Fournier B., Philpott D.J. Recognition of Staphylococcus aureus by the innate immune system. Clin Microbiol Rev 2005, 18:521-540.
35. Garzoni C., Kelley W.L. Return of the Trojan horse: intracellular phenotype switching and immune evasion by Staphylococcus aureus. EMBO Mol Med 2011, 3:115-117.
36. Kim H.K., Thammavongsa V., Schneewind O., Missiakas D. Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol 2012, 15:92-99.
37. Krishna S., Miller L.S. Innate and adaptive immune responses against Staphylococcus aureus skin infections. Semin Immunopathol 2012, 34:261-280.
38. Parker D., Prince A. Immunopathogenesis of Staphylococcus aureus pulmonary infection. Semin Immunopathol 2012, 34:281-297.
39. Anderson A.S., Miller A.A., Donald R.G., Scully I.L., Nanra J.S., Cooper D., et al. Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccines Immunother 2012, 8.
40. Anderson A.S., Scully I.L., Timofeyeva Y., Murphy E., McNeil L.K., Mininni T., et al. Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis. J Infect Dis 2012, 205:1688-1696.
41. Proctor R.A. Challenges for a universal Staphylococcus aureus vaccine. Clin Infect Dis 2012, 54:1179-1186.
42. Daum R.S., Progress Spellberg B. Toward a Staphylococcus aureus vaccine. Clin Infect Dis 2012, 54:560-567.
43. Ahmed E.B., Wang T., Daniels M., Alegre M.L., Chong A.S. IL-6 induced by Staphylococcus aureus infection prevents the induction of skin allograft acceptance in mice. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 2011, 11:936-946.
44. den Dunnen J., Vogelpoel L.T., Wypych T., Muller F.J., de Boer L., Kuijpers T.W., et al. IgG opsonization of bacteria promotes Th17 responses via synergy between TLRs and FcgammaRIIa in human dendritic cells. Blood 2012, 120:112-121.
45. Frank K.M., Zhou T., Moreno-Vinasco L., Hollett B., Garcia J.G., Bubeck Wardenburg J. Host response signature to Staphylococcus aureus alpha-hemolysin implicates pulmonary Th17 response. Infect Immun 2012, 80:3161-3169.
46. Gillrie M.R., Zbytnuik L., McAvoy E., Kapadia R., Lee K., Waterhouse C.C., et al. Divergent roles of Toll-like receptor 2 in response to lipoteichoic acid and Staphylococcus aureus in vivo. Eur J Immunol 2010, 40:1639-1650.
47. Islander U., Andersson A., Lindberg E., Adlerberth I., Wold A.E., Superantigenic Rudin A. Staphylococcus aureus stimulates production of interleukin-17 from memory but not naive T cells. Infect Immun 2010, 78:381-386.
48. Joshi A., Pancari G., Cope L., Bowman E., Cua D., Proctor R., et al. Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum Vaccines Immunotherap 2012, 8:0-10.
49. Kim M.R., Hong S.W., Choi E.B., Lee W.H., Kim Y.S., Jeon S.G., et al. Staphylococcus aureus-derived extracellular vesicles induce neutrophilic pulmonary inflammation via both Th1 and Th17 cell responses. Allergy 2012, 67:1271-1281.
50. Niebuhr M., Gathmann M., Scharonow H., Mamerow D., Mommert S., Balaji H., et al. Staphylococcal alpha-toxin is a strong inducer of interleukin-17 in humans. Infect Immun 2011, 79:1615-1622.
51. Pancari G., Fan H., Smith S., Joshi A., Haimbach R., Clark D., et al. Characterization of the mechanism of protection mediated by CS-D7, a monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB). Front Cell Infect Microbiol 2012, 2:36.
52. Prabhakara R., Harro J.M., Leid J.G., Harris M., Shirtliff M.E. Murine immune response to a chronic Staphylococcus aureus biofilm infection. Infect Immun 2011, 79:1789-1796.
53. Zielinski C.E., Mele F., Aschenbrenner D., Jarrossay D., Ronchi F., Gattorno M., et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012, 484:514-518.
54. Ma C.S., Chew G.Y., Simpson N., Priyadarshi A., Wong M., Grimbacher B., et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 2008, 205:1551-1557.
55. Monteil M., Hobbs J., Citron K. Selective immunodeficiency affecting staphylococcal response. Lancet 1987, 2:880-883.
56. Mayer-Scholl A., Averhoff P., Zychlinsky A. How do neutrophils and pathogens interact. Curr Opin Microbiol 2004, 7:62-66.
57. Wang F. The signaling mechanisms underlying cell polarity and chemotaxis. Cold Spring Harbor Perspect Biol 2009, 1:a002980.
58. Nanra J.S., Buitrago S.M., Crawford S., Ng J., Fink P.S., Hawkins J., et al. Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccines Immunotherap 2012, 9.
59. Bodey G., Buckley M., Sathe Y.S., Freireich E. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966, 64:328-340.
60. Quie P.G., White J.G., Holmes B., Good R.A. In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood. J Clin Invest 1967, 46:668-679.
61. Johnston R.B., Keele B.B., Misra H.P., Lehmeyer J.E., Webb L.S., Baehner R.L., et al. The role of superoxide anion generation in phagocytic bactericidal activity, Studies with normal and chronic granulomatous disease leukocytes. J Clin Invest 1975, 55:1357-1372.
62. Curnutte J. Hematology of infancy and childhood 1993, Saunders, Philadelphia, PA.
63. Handin R.L. Harrison's principles of internal medicine 1998, McGraw-Hill, Texas. 14th ed.
64. Lorenz E., Mira J.P., Cornish K.L., Arbour N.C., Schwartz D.A. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000, 68:6398-6401.
65. Picard C., Puel A., Bonnet M., Ku C.L., Bustamante J., Yang K., et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003, 299:2076-2079.
66. Proctor R.A. Is there a future for a Staphylococcus aureus vaccine. Vaccine 2012, 30:2921-2927.
67. Akins P.T., Belko J., Banerjee A., Guppy K., Herbert D., Slipchenko T., et al. Perioperative management of neurosurgical patients with methicillin-resistant Staphylococcus aureus. J Neurosurg 2010, 112:354-361.
68. Bassetti M., Melica G., Cenderello G., Rosso R., Di Biagio A., Bassetti D. Gram-positive bacterial resistance, a challenge for the next millennium. Panminerva Med 2002, 44:179-184.
69. Cameron D.R., Howden B.P., Peleg A.Y. The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes. Clin Infect Dis Off Pub Infect Dis Soc Am 2011, 53:576-582.
70. Chao D., Nanda A. Spinal epidural abscess: a diagnostic challenge. Am Family Phys 2002, 65:1341-1346.
71. Concia E., Prandini N., Massari L., Ghisellini F., Consoli V., Menichetti F., et al. Osteomyelitis: clinical update for practical guidelines. Nucl Med Commun 2006, 27:645-660.
72. Cornaglia G., Rossolini G.M. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Clin Microbiol Infect Off Pub Eur Soc Clin Microbiol Infect Dis 2009, 15:218-223.
73. Deasy J. The antibiotic challenge: changing clinical management of infections. JAAPA 2009, 22:22-26.
74. Harbarth S. Control of endemic methicillin-resistant Staphylococcus aureus - recent advances and future challenges. Clin Microbiol Infect Off Pub Eur Soc Clin Microbiol Infect Dis 2006, 12:1154-1162.
75. Hiramatsu K. Vancomycin resistance in staphylococci. Drug Resist Updates Rev Comment Antimicrob Anticancer Chemother 1998, 1:135-150.
76. Jorge L.S., Chueire A.G., Rossit A.R. Osteomyelitis: a current challenge. Braz J Infect Dis Off Pub Braz Soc Infect Dis 2010, 14:310-315.
77. Aboelela S.W., Saiman L., Stone P., Lowy F.D., Quiros D., Larson E. Effectiveness of barrier precautions and surveillance cultures to control transmission of multidrug-resistant organisms: a systematic review of the literature. Am J Infect Control 2006, 34:484-494.
78. Lowy F.D. Staphylococcus aureus infections. N Engl J Med 1998, 339:520-532.
79. Hawkins J., Kodali S., Matsuka Y.V., McNeil L.K., Mininni T., Scully I.L., et al. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clin Vaccine Immunol. 2012, 19:1641-1650.
80. Dale J.B. Current status of group A streptococcal vaccine development. Adv Exp Med Biol 2008, 609:53-63.
81. Jodar L., Butler J., Carlone G., Dagan R., Goldblatt D., Kayhty H., et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003, 21:3265-3272.
82. Romero-Steiner S., Musher D.M., Cetron M.S., Pais L.B., Groover J.E., Fiore A.E., et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis Off Pub Infect Dis Soc Am 1999, 29:281-288.
83. Musher D.M., Groover J.E., Rowland J.M., Watson D.A., Struewing J.B., Baughn R.E., et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis Off Pub Infect Dis Soc Am 1993, 17:66-73.
84. Hawkins J., Kodali S., Matsuka Y.V., McNeil L.K., Mininni T., Scully I.L., et al. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. CVI 2012, 19:1641-1650.
85. Tkaczyk C., Hua L., Varkey R., Shi Y., Dettinger L., Woods R., et al. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. CVI 2012, 19:377-385.
86. Mishra R.P., Mariotti P., Fiaschi L., Nosari S., Maccari S., Liberatori S., et al. Staphylococcus aureus FhuD2 is involved in the early phase of staphylococcal dissemination and generates protective immunity in mice. J Infect Dis 2012, 206:1041-1049.
87. Kim H.K., DeDent A., Cheng A.G., McAdow M., Bagnoli F., Missiakas D.M., et al. IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 2010, 28:6382-6392.
88. Harro C., Betts R., Orenstein W., Kwak E.J., Greenberg H.E., Onorato M.T., et al. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. CVI 2010, 17:1868-1874.
89. Fowler VG AK, Moreira E, Moustafa M, Isgro F, Boucher H, FIDSA, et al. Efficacy and safety of an investigational Staphylococcus aureus vaccine in preventing bacteremia and deep sternal wound infections after cardiothoracic surgery. IDWeek. San Diego, CA; 2012.
90. Brown M., Kowalski R., Zorman J., Wang X.M., Towne V., Zhao Q., et al. Selection and characterization of murine monoclonal antibodies to Staphylococcus aureus iron-regulated surface determinant B with functional activity in vitro and in vivo. CVI 2009, 16:1095-1104.
91. Ebert T., Smith S., Pancari G., Clark D., Hampton R., Secore S., et al. A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. Hum Antibodies 2010, 19:113-128.
92. Shinefield H., Black S., Fattom A., Horwith G., Rasgon S., Ordonez J., et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002, 346:491-496.
93. Fattom A.I., Horwith G., Fuller S., Propst M., Naso R. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine 2004, 22:880-887.
94. Matalon AM, M.; Buerkert, J.; Block, G; Hohenboken, M.; Fattom, A.; Horwirth, G., Rasmussen, H., Damasco, S.; Boutriau, D. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugate investigational vaccine in adults on haemodialysis: Phase III randomized study. International symposium on staphylococcal infections. Lyon, France; 2012. p. 9-114.
95. Richmond PNM, Marshall H, Shakib S, Hodsman P, Jiang Q, Cooper D, et al. Safety, Tolerability, and Immunogenicity of a novel 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: results of a randomized, placebo controlled Phase 1 first-in-human study. IDWeek. San Diego, CA; 2012.
96. Anwar S., Prince L.R., Foster S.J., Whyte M.K., Sabroe I. The rise and rise of Staphylococcus aureus: laughing in the face of granulocytes. Clin Exp Immunol 2009, 157:216-224.
97. Clarke S.R., Foster S.J. Surface adhesins of Staphylococcus aureus. Adv Microb Phys 2006, 51:187-224.
98. Anderson A.S., Scully I.L., Timofeyeva Y., Murphy E., McNeil L.K., Mininni T., et al. The Staphylococcus aureus transporter MntC is a highly conserved cell surface protein that elicits protective immunity against both S. aureus and Staphylococcus epidermidis. J Infect Dis 2012.
99. Stranger-Jones Y.K., Bae T., Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci 2006, 103:16942-16947.
100. Bagnoli F., Bertholet S., Grandi G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol 2012, 2:16.
101. Dunman P.M., Nesin M. Passive immunization as prophylaxis: when and where will this work. Curr Opin Pharmacol 2003, 3:486-496.
102. Projan S.J., Nesin M., Dunman P.M. Staphylococcal vaccines and immunotherapy: to dream the impossible dream. Curr Opin Pharmacol 2006, 6:473-479.
103. Menzies B.E., Kernodle D.S. Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect Immun 1996, 64:1839-1841.
104. Bubeck Wardenburg J., Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 2008, 205:287-294.
105. Proctor R.A. Challenges for a universal Staphylococcus aureus vaccine. Clin Infect Dis Off Pub Infect Dis Soc Am 2012, 54:1179-1186.
106. Tseng C.W., Kyme P.A., Arruda A., Ramanujan V.K., Tawackoli W., Liu G.Y. Innate immune dysfunctions in aged mice facilitate the systemic dissemination of methicillin-resistant S. aureus. PLoS One 2012, 7:e41454.
107. Fagan R.L., Bulens F., Mu S., Nadle Y., Bamberg J., Petit W., et al. Estimates of Invasive Methicillin-Resistant Staphylococcus aureus Infection Rates by Specific Population Groups. ID Week. San Diego 2012.
108. Korinek A.M., Golmard J.L., Elcheick A., Bismuth R., van Effenterre R., Coriat P., et al. Risk factors for neurosurgical site infections after craniotomy: a critical reappraisal of antibiotic prophylaxis on 4578 patients. Brit J Neurosurg 2005, 19:155-162.
109. Nery P.B., Fernandes R., Nair G.M., Sumner G.L., Ribas C.S., Menon S.M., et al. Device-related infection among patients with pacemakers and implantable defibrillators: incidence, risk factors, and consequences. J Cardiovas Electrophysiol 2010, 21:786-790.
110. Ridgeway S., Wilson J., Charlet A., Kafatos G., Pearson A., Coello R. Infection of the surgical site after arthroplasty of the hip. J Bone Joint Surg Brit Vol 2005, 87:844-850.
111. Rao S.B., Vasquez G., Harrop J., Maltenfort M., Stein N., Kaliyadan G., et al. Risk factors for surgical site infections following spinal fusion procedures: a case-control study. Clin Infect Dis Off Pub Infect Dis Soc Am 2011, 53:686-692.
112. Bratzler D.W., Houck P.M., Surgical Infection Prevention Guidelines Writers W., American Academy of Orthopaedic S., American Association of Critical Care N., American Association of Nurse A., et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis Off Pub Infect Dis Soc Am 2004, 38:1706-1715.
113. Sands K., Vineyard G., Platt R. Surgical site infections occurring after hospital discharge. J Infect Dis 1996, 173:963-970.
114. Wloch C., Wilson J., Lamagni T., Harrington P., Charlett A., Sheridan E. Risk factors for surgical site infection following caesarean section in England: results from a multicentre cohort study. BJOG 2012, 119:1324-1333.
115. Bleasdale S.C., Trick W.E., Gonzalez I.M., Lyles R.D., Hayden M.K., Weinstein R.A. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 2007, 167:2073-2079.
116. Fakih M.G., Sharma M., Khatib R., Berriel-Cass D., Meisner S., Harrington S., et al. Increase in the rate of sternal surgical site infection after coronary artery bypass graft: a marker of higher severity of illness. Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am 2007, 28:655-660.
117. Taylor G., Herrick T., Mah M. Wound infections after hysterectomy: opportunities for practice improvement. Am J Infect Control 1998, 26:254-257.
118. Khan U.D. Breast augmentation, antibiotic prophylaxis, and infection: comparative analysis of 1628 primary augmentation mammoplasties assessing the role and efficacy of antibiotics prophylaxis duration. Aesthet Plast Surg 2010, 34:42-47.
119. Mangram A.J., Horan T.C., Pearson M.L., Silver L.C., Jarvis W.R. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am 1999, 20:250-278. [quiz 79-80].
120. Belsky D.S., Teates C.D., Hartman M.L. Case report: diabetes mellitus as a predisposing factor in the development of pyomyositis. Am J Med Sci 1994, 308:251-254.
121. Hamel M., Zoutman D., O'Callaghan C. Exposure to hospital roommates as a risk factor for health care-associated infection. Am J Infect Control 2010, 38:173-181.
122. Hsu R.B., Chen R.J., Wang S.S., Chu S.H. Infected aortic aneurysms: clinical outcome and risk factor analysis. J Vasc Surg 2004, 40:30-35.
123. Jensen A.G., Wachmann C.H., Poulsen K.B., Espersen F., Scheibel J., Skinhoj P., et al. Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Arch Intern Med 1999, 159:1437-1444.
124. Kim E.S., Kim H.B., Song K.H., Kim Y.K., Kim H.H., Jin H.Y., et al. Prospective nationwide surveillance of surgical site infections after gastric surgery and risk factor analysis in the Korean Nosocomial Infections Surveillance System (KONIS). Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am 2012, 33:572-580.
125. Spelman D.W., Russo P., Harrington G., Davis B.B., Rabinov M., Smith J.A., et al. Risk factors for surgical wound infection and bacteraemia following coronary artery bypass surgery. Austr NZ J Surg 2000, 70:47-51.
126. Centofanti P., Savia F., La Torre M., Ceresa F., Sansone F., Veglio V., et al. A prospective study of prevalence of 60-days postoperative wound infections after cardiac surgery, an updated risk factor analysis. J Cardiovasc Surg 2007, 48:641-646.
127. Dodds Ashley E.S., Carroll D.N., Engemann J.J., Harris A.D., Fowler V.G., Sexton D.J., et al. Risk factors for postoperative mediastinitis due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis Off Pub Infect Dis Soc Am 2004, 38:1555-1560.
128. Fang S., Skeete D., Cullen J.J. Preoperative risk factors for postoperative Staphylococcus aureus nosocomial infections. Surg Technol Int 2004, 13:35-38.
129. Sorensen L.T., Horby J., Friis E., Pilsgaard B., Jorgensen T. Smoking as a risk factor for wound healing and infection in breast cancer surgery. Eur J Surg Oncol J Eur Soc Surg Oncol Brit Assoc Surg Oncol 2002, 28:815-820.
130. Yu H, Mardekian J, Strutton D, Girgenti D. Characterizing Staphylococcus aureus infections following elective surgeries in US hospitals. International conference on antimicrobial agents and chemotherapeutics. San Francisco, CA; 2012.
131. Fitzgerald S.F., O'Gorman J., Morris-Downes M.M., Crowley R.K., Donlon S., Bajwa R., et al. A 12-year review of Staphylococcus aureus bloodstream infections in haemodialysis patients: more work to be done. J Hosp Infect 2011, 79:218-221.
132. Descamps-Latscha B., Chatenoud L. T cells and B cells in chronic renal failure. Semin Nephrol 1996, 16:183-191.
133. Schollmeyer P., Bozkurt F. The immune status of the uremic patient: hemodialysis vs CAPD. Clin Nephrol 1988, 30(Suppl. 1):S37-S40.
134. Kay N.E., Raij L.R. Immune abnormalities in renal failure and hemodialysis. Blood Purif 1986, 4:120-129.
135. Kotiranta-Ainamo A., Rautonen J., Rautonen N. Imbalanced cytokine secretion in newborns. Biol Neonate 2004, 85:55-60.
136. Chelvarajan R.L., Collins S.M., Doubinskaia I.E., Goes S., Van Willigen J., Flanagan D., et al. Defective macrophage function in neonates and its impact on unresponsiveness of neonates to polysaccharide antigens. J Leukocyte Biol 2004, 75:982-994.
137. Marodi L. Innate cellular immune responses in newborns. Clin Immunol 2006, 118:137-144.
138. Merck. Efficacy, Immunogenicity, and safety of a single dose of V710 in adult patients scheduled for cardiothoracic surgery (V710-003 AM2). ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2012.
139. NabiBiopharmaceuticals. Study to evaluate the effectiveness of StaphVAX in adults on hemodialysis. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2006.
140. NabiBiopharmaceuticals. StaphVAX in cardiovascular surgery patients. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2007.
141. Bristol-Myers_Squibb. Safety and efficacy of Veronate® versus placebo in preventing nosocomial staphylococcal sepsis in premature infants. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2006.
142. Biosynexus_Incorporated. Safety and efficacy of pagibaximab injection in very low birth weight neonates for prevention of staphylococcal sepsis. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2011.
143. Pfizer evaluation of a single vaccination of one of three ascending dose levels of a 4-antigen staphylococcus aureus vaccine (SA4Ag) and a single dose level of a 3-antigen staphylococcus aureus vaccine (SA3Ag) in healthy adults aged 65 to <86years. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2012.
144. Uniformed_Services_University_of_the_Health_Sciences. Staphylococcus aureus toxoids phase 1-2 vaccine trial. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2012.
145. GlaxoSmithKline. A study to evaluate the safety, reactogenicity and immunogenicity of GSK biologicals' staphylococcal investigational vaccine in healthy adults. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2012.
146. Vaccine_Research_International_Plc. Phase I trial. Birmingham, UK. Vaccine Research International Plc; 2013.
147. Sanofi. Pharmacokinetics, Pharmacodynamics and safety evaluation of SAR279356 in intensive care unit mechanically ventilated patients. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2013.
148. NabiBiopharmaceuticals. Safety study of an intravenous staphylococcus aureus immune globulin (human), [altastaph] in low-birth-weight-neonates. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2012.
149. Inhibitex Aurexis® in cystic fibrosis subjects chronically colonized with Staphylococcus aureus in their lungs. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2006.
150. Inhibitex clinical trial comparing safety and pharmacokinetics of standard antibiotic therapy, plus Aurexis® or placebo, for treatment of Staphylococcus aureus bacteremia (SAB). ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2005.
151. Rupp M.E., Holley H.P., Lutz J., Dicpinigaitis P.V., Woods C.W., Levine D.P., et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007, 51:4249-4254.
152. NabiBiopharmaceuticals. Safety and behavior of S. Aureus immune globulin intravenous (human), [altastaph] in patients with S. aureus bacteremia and continuing fever. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2012.
153. Kenta_Biotech_Ltd. Safety, pharmacokinetics and efficacy of KBSA301 in severe pneumonia (S. aureus). ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2013.
154. NeuTec_Pharma. Aurograb and vancomycin in MRSA infection. ClinicalTrialsgov. Bethesda, MD: National Library of Medicine (US); 2006.